Effects of siRNA mediated Cdc2 silencing on MG63 cell proliferation and apoptosis

Molecular Medicine Reports

Volumn 7, Issue 2, 2013, Pages 466-470

  Que, Xiang Yong ^a   Li, Yi ^a   Han, Yu ^b   Li, Xin Zhi ^a  

^a Renhe Hospital of Three Gorges University   (China)

^b CHINA THREE GORGES UNIVERSITY   (China)

Author keywords

Apoptosis; Cdc2; Osteosarcoma MG63 cells; Proliferation; SiRNA

Indexed keywords

CYCLIN DEPENDENT KINASE 2; PROTEIN BCL 2; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CELL ASSAY; CELL CYCLE; CELL CYCLE PHASE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; OSTEOSARCOMA CELL; PLASMID; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 2; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84873814375     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1209     Document Type: Article

References (25)

1. Picci P: Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2: 6, 2007.
2. Chou AJ, Geller DS and Gorlick R: Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 10: 315-327, 2008.
3. Tan ML, Choong PF and Dass CR: Osteosarcoma: Conventional treatment vs. gene therapy. Cancer Biol Ther 8: 106-117, 2009.
4. Broadhead ML, Clark JC, Choong PF and Dass CR: Making gene therapy for osteosarcoma a reality. Expert Rev Anticancer Ther 10: 477-480, 2010.
5. Li XZ, Meng L, Chen AM, Guo FJ, Luo ZQ and Zeng H: Screening of differentially expressed genes in osteosarcoma cell lines with various metastatic potentialities. Zhonghua Zhong Liu Za Zhi 1: 71-76, 2010 (In Chinese).
6. Li XZ, Meng L, Chen AM, Guo FJ, Luo ZQ and Zeng H: Differentially expressed gene in osteosarcoma cell lines with different metastatic potentials. J Nanjing Med Univ 23: 352-358, 2009.
7. Chen H, Huang Q, Dong J, Zhai DZ, Wang AD and Lan Q: Overexpression of CDC2/CyclinB1 in gliomas, and CDC2 depletion inhibits proliferation of human glioma cells in vitro and in vivo. BMC Cancer 8: 29, 2008.
8. Winkler K, Beron G, Kotz R, et al: Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol 2: 617-624, 1984.
9. Marina NM, Pratt CB, Rao BN, Shema SJ and Meyer WH: Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis. Cancer 70: 2722-2727, 1992.
10. Kempf-Bielack B, Bielack SS, Jürgens H, et al: Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23: 559-568, 2005.
11. Oshima Y, Sasaki Y, Negishi H, et al: Antitumor effect of adenovirus-mediated p53 family gene transfer on osteosarcoma cell lines. Cancer Biol Ther 6: 1058-1066, 2007.
12. Walkley CR, Qudsi R, Sankaran VG, et al: Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes 22: 1662-1676, 2008.
13. Liang X, Da M, Zhuang Z, et al: Effects of Survivin on cell proliferation and apoptosis in MG-63 cells in vitro. Cell Biol Int 33: 119-124, 2009.
14. Wu YF, Liang XJ, Liu YY, et al: +Antisense oligonucleotide targeting survivin inhibits growth by inducing apoptosis in human osteosarcoma cells MG-63. Neoplasma 57: 501-506, 2010.
15. Kim C, Shin E, Hong S, et al: Clinical value of ezrin expression in primary osteosarcoma. Cancer Res Treat 41: 138-144, 2009.
16. Wang YF, Shen JN, Xie XB, Wang J and Huang G: Expression change of ezrin as a prognostic factor in primary osteosarcoma. Med Oncol 28 (Suppl 1): S636-S643, 2011.
17. Xu N and Chang DC: Different thresholds of MPF inactivation are responsible for controlling different mitotic events in mammalian cell division. Cell Cycle 6: 1639-1645, 2007.
18. Kim DH: Prognostic implications of cyclinB1, p34cdc2, p27(Kip1) and p53 expression in gastric cancer. Yonsei Med J 48: 694-700, 2007.
19. Chang JT, Wang HM, Chang KW, et al: Identification of differentially expressed genes in oral squamous cell carcinoma (OSCC): overexpression of NPM, CDK1 and NDRG1 and underexpression of CHES1. Int J Cancer 114: 942-949, 2005.
20. Diril MK, Ratnacaram CK, Padmakumar VC, et al: Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration. Proc Natl Acad Sci USA 109: 3826-3831, 2012.
21. Kim SJ, Nakayama S, Miyoshi Y, et al: Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. Ann Onco 19: 68-72, 2008.
22. Choi HJ and Zhu BT: Critical role of cyclin B1/Cdc2 up-regulation in the induction of mitotic prometaphase arrest in human breast cancer cells treated with 2-methoxyestradiol. Biochim Biophys Acta 1823: 1306-1315, 2012.
23. Zhao MY, Auerbach A, D'Costa AM, et al: Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy. Clin Cancer Res 15: 1708-1720, 2009.
24. Meyer A, Merkel S, Brückl W, et al: Cdc2 as prognostic marker in stage UICC II colon carcinomas. Eur J Cancer 45: 1466-1473, 2009.
25. Shi HR and Zhang RT: Expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer. Ai Zheng 28: 882-885, 2009 (In Chinese).